• #LGM Pharma is a Voriconazole CAS# 137234-62-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 137234-62-9
  • AHFC code:
  • Synonyms: (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol, 4-Pyrimidineethanol, alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (alphaR,betaS)-, DRG-0301, UK-109,496, UNII-JFU09I87TR, VFEND, VFEND I.V., Voriconazole, Vorikonazole, VRC
  • ATC Code: J02AC03
  • Chemical Formula: C16-H14-F3-N5-O
  • Molecular Weight: 349.315
  • Assay/Purity: Typically NLT 98%
  • DrugBank: APRD00543
  • SMILES: c1(c([C,,]([C,H](c2ncncc2F)C)(Cn2cncn2)O)ccc(F)c1)F
  • InChl: 1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
  • PubChem: 71616
  • IUPAC: (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol

Additional Details

Invasive aspergillosisVfend 200mg oral tabletVoriconazole has become the new standard of care in the treatment of invasive aspergillosis, which may occur in immunocompromised patients, including allogeneic BMT, other hematologic cancers, and solid organ transplants. This is based on the results of a large, randomized study in which voriconazole proved superior to amphotericin B with 53% complete or partial response, compared with 32% for amphotericin B. Importantly, voriconazole also offered a 22% greater survival benefit over amphotericin B, with 71% of voriconazole patients still alive at week 12. Only 13% of patients who received initial therapy with voriconazole died from invasive aspergillosis, compared with 29% of patients who initially received amphotericin B. Voriconazole was also better tolerated than amphotericin B, with significantly fewer serious adverse effects and a longer duration of therapy. Note that the design of these studies has been called into question, and some still consider (liposomal) amphotericin B as the drug of choice.
Mode of Action:
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials